 WEST LAFAYETTE, Ind., April 23, 2021 GLOBE NEWSWIRE -- Inotiv, Inc. NASDAQ:NOTV the Company, We, Our or Inotiv, a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the closing of an underwritten public offering of 3,044,117 of its common shares, including 397,058 common shares sold pursuant to the full exercise by the underwriter of its option to purchase additional shares to cover over-allotments. All of the shares were sold at a price to the public of 17.00 per share. The gross proceeds to the Company from this offering, before deducting the underwriting discount and offering expenses payable by the Company, were approximately 51.7 million. 